Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.59 |
| ▸ | HTR6 | P50406 | 7/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.46 |
| ▸ | HTR1A | P08908 | 4/20 | 0.46 |
| ▸ | HTR2A | P28223 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24371605 | 0.89 | PTGS2 (0.47) | HTR2CHTR2A | |
| SCHEMBL5937352 | 0.86 | HTR6 (0.48) | HTR2CHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6789169 | 0.82 | HTR6 (0.46) | HTR2CHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22542016 | 0.81 | SLC6A2 (0.63) | HTR2CHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2707057 | 0.81 | HTR2C (0.63) | HTR2CHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15070072 | 0.81 | HTR2C (0.55) | HTR2CHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6709234 | 0.79 | TRPA1 (0.47) | HTR2CHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25085586 | 0.79 | HTR6 (0.51) | HTR2CHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5669793 | 0.79 | HTR2C (0.61) | HTR2CHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23712339 | 0.79 | HTR2C (0.61) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4188396-A | ANTIDEPRESSANTS | CIBA-GEIGY CORPORATION (US) | 1980-02-12 | — | — | US | claimed |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | disclosed |
| EP-1351936-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002055496-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
| US-4188396-A | ANTIDEPRESSANTS | CIBA-GEIGY CORPORATION (US) | 1980-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | LDLR, NR1H2, NCOR1 | HTR2C 1120/4885HTR6 705/4885SLC6A2 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.